Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.65 |
| ▸ | MAPT | P10636 | 2/20 | 0.65 |
| ▸ | NPC1 | O15118 | 1/20 | 0.60 |
| ▸ | RAB9A | P51151 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | RECQL | P46063 | 1/20 | 0.58 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.57 |
| ▸ | AKR1C3 | P42330 | 3/20 | 0.53 |
| ▸ | AKR1C2 | P52895 | 3/20 | 0.53 |
| ▸ | UBE2M | P61081 | 1/20 | 0.53 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.53 |
| ▸ | KCNJ6 | P48051 | 1/20 | 0.52 |
| ▸ | KCNJ5 | P48544 | 1/20 | 0.52 |
| ▸ | KCNJ3 | P48549 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL147214 | 0.93 | MAPT (0.67) | NPSR1MAPTNPC1RAB9AKMT2A | |
| SCHEMBL7744394 | 0.88 | NPSR1 (0.64) | NPSR1MAPTNPC1RAB9AKMT2A | |
| SCHEMBL144387 | 0.88 | NPSR1 (0.76) | NPSR1MAPTNPC1RAB9AKMT2A | |
| SCHEMBL1900773 | 0.83 | NPSR1 (0.90) | NPSR1MAPTNPC1RAB9AKMT2A | |
| SCHEMBL144199 | 0.82 | NPSR1 (0.70) | NPSR1MAPTRECQLPTGDR2AKR1C3 | |
| SCHEMBL146791 | 0.81 | NPSR1 (0.78) | NPSR1MAPTNPC1RAB9AKMT2A | |
| SCHEMBL7744959 | 0.79 | NPSR1 (1.00) | NPSR1MAPTNPC1RAB9AKMT2A | |
| SCHEMBL1902360 | 0.77 | KMT2A (0.57) | NPSR1MAPTNPC1RAB9AKMT2A | |
| SCHEMBL1897475 | 0.77 | NPSR1 (0.48) | NPSR1MAPTLMNARECQLPTGDR2 | |
| SCHEMBL3077688 | 0.75 | P2RY14 (0.54) | MAPTLMNARECQLKCNJ6KCNJ5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120059047-A1 | DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR | VERVA PHARMACEUTICALS PTY LTD (AU) | 2012-03-08 | — | — | US | disclosed |
| EP-1252156-B1 | BLOCKADE OF VOLTAGE DEPENDENT SODIUM CHANNELS | UCL BUSINESS PLC (GB) | 2011-05-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059047-A1 | DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR | FGF1, FABP4, FGF2 | NPSR1 3871/4885MAPT 4367/4885NPC1 2593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.